the 3 groups. On follow up there were no significant differences in cause of mortality, progressi... more the 3 groups. On follow up there were no significant differences in cause of mortality, progression of liver disease, new LRE and development of new onset diabetes and hypertension across the BMI groups. Conclusion: Patients with obesity may have greater metabolic derangements as compared to normal or overweight individuals but this does not translate to more severe liver disease or adverse outcomes in these patients. Although intuitive, the dose response relationship between BMI and severity of NAFLD is not linear.
the 3 groups. On follow up there were no significant differences in cause of mortality, progressi... more the 3 groups. On follow up there were no significant differences in cause of mortality, progression of liver disease, new LRE and development of new onset diabetes and hypertension across the BMI groups. Conclusion: Patients with obesity may have greater metabolic derangements as compared to normal or overweight individuals but this does not translate to more severe liver disease or adverse outcomes in these patients. Although intuitive, the dose response relationship between BMI and severity of NAFLD is not linear.
Uploads
Papers by Shekhar Swaroop